OncoMatch/Clinical Trials/NCT05210374
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Is NCT05210374 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Disulfiram and Copper Gluconate for relapsed sarcomas.
Treatment: Disulfiram · Copper Gluconate · Liposomal Doxorubicin (Doxil) — The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Blood counts
Absolute neutrophil count ≥1,000/mcL; Platelet count ≥ 100,000/mcL
Kidney function
Serum Creatinine ≤1.5X institutional limit of normal
Liver function
Total bilirubin within normal institutional limits; AST (SGOT) ≤ 2.5 X institutional upper limit of normal; ALT (SGPT) ≤ 2.5 X institutional upper limit of normal
Must have normal organ and marrow function as defined below: * Absolute neutrophil count ≥1,000/mcL * Platelet count ≥ 100,000/mcL * Total bilirubin within normal institutional limits * AST (SGOT) ≤ 2.5 X institutional upper limit of normal * ALT (SGPT) ≤ 2.5 X institutional upper limit of normal * Serum Creatinine ≤1.5X institutional limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cleveland Clinic, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify